Further studies have thus led to the understanding that cancer vaccines can be effective in the following conditions: (1) a low tumoral mass burden; (2) lowered or reduced immunosuppression via chemotherapy or immune checkpoint inhibitors; (3) a strong and sustainable specific immune response guided by CD4+ TH1 cells and CD8+ CTLs [207]. This evidence concerns the gene CD8A and cancer.